Lorenza Rimassa
YOU?
Author Swipe
View article: Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR
Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR Open
View article: Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis Open
This study highlights the genomic landscape of advanced HCC, identifying cell cycle and apoptosis, DNA damage and control, WNT, and p53 as the key affected pathways. Further research is warranted to confirm such findings.
View article: Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review
Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review Open
Cholangiocarcinoma (CCA) represents a diverse group of malignancies. It is often identified at a late stage after the opportunity for curable resection has passed. An international educational meeting on CCA was held in Barcelona in Septem…
View article: Navigating second-line therapy after immunotherapy in advanced HCC
Navigating second-line therapy after immunotherapy in advanced HCC Open
View article: Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab Open
Spontaneously immunogenic hepatocellular carcinoma (HCC), identified by a dense immune cell infiltrate (ICI), responds better to immunotherapy, although no validated biomarker exists to identify these cases. We used machine learning (ML) t…
View article: Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study Open
Background & Aims: Atezolizumab plus bevacizumab (A+B) is a standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). However, optimal sequencing strategies after A+B failure remain undefined. Methods: LEVIATHAN…
View article: Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab Open
Background and Aims Hepatitis C virus (HCV) is a key driver of hepatocellular carcinoma (HCC). However, the impact of HCV eradication on systemic therapy remains unclear. We aimed to assess the safety and efficacy of direct‐acting antivira…
View article: Evolving precision: Updates in targeted therapy for cholangiocarcinoma
Evolving precision: Updates in targeted therapy for cholangiocarcinoma Open
The development of Next-Generation Sequencing (NGS) techniques for extended genomic profiling has led to the identification of actionable molecular alterations in approximately half of the patients with biliary tract cancer (BTC), with the…
View article: From the Editor’s Desk...
From the Editor’s Desk... Open
View article: Does adjuvant therapy improve survival in patients undergoing pancreaticoduodenectomy for distal cholangiocarcinoma? A systematic review, meta-analysis and meta-regression
Does adjuvant therapy improve survival in patients undergoing pancreaticoduodenectomy for distal cholangiocarcinoma? A systematic review, meta-analysis and meta-regression Open
The role of adjuvant therapy (AT) after pancreaticoduodenectomy (PD) for distal cholangiocarcinoma (DC) remains controversial. This systematic review and meta-analysis aimed to evaluate the impact of AT on overall survival (OS) and disease…
View article: Breaking Barriers for Intensive Care Admission in Patients With Advanced <scp>HCC</scp> on Immunotherapy
Breaking Barriers for Intensive Care Admission in Patients With Advanced <span>HCC</span> on Immunotherapy Open
Background and Aims Intensive Care Unit (ICU) admission is usually denied to patients with advanced hepatocellular carcinoma (HCC) due to the perceived poor prognosis associated with both cirrhosis and liver cancer. However, immunotherapy …
View article: Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study Open
Introduction: The potential for curative conversion with immunotherapy-based systemic treatment used with noncurative intent in patients with hepatocellular carcinoma (HCC) remains debated. This study aimed to provide a reliable epidemiolo…
View article: Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis
Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis Open
Background/Objectives: Biliary tract cancers (BTCs) are aggressive malignancies with a poor prognosis. Surgery remains the only curative option, yet recurrence rates are high, and the role of adjuvant chemotherapy remains debated. This stu…
View article: Negative impact of corticosteroid use on outcome in patients with advanced <scp>BTCs</scp> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
Negative impact of corticosteroid use on outcome in patients with advanced <span>BTCs</span> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population Open
In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real‐world analysis aims to evaluate the impact of conco…
View article: Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma Open
Background Despite improved outcomes with atezolizumab plus bevacizumab (A+B) in hepatocellular carcinoma (HCC), primary refractoriness (PRef), characterised by early progression or short-lived disease stabilisation following treatment, re…
View article: 337P Ivosidenib for IDH1-mutant intrahepatic cholangiocarcinoma: Insights from a multicenter real-world study
337P Ivosidenib for IDH1-mutant intrahepatic cholangiocarcinoma: Insights from a multicenter real-world study Open
View article: 175P Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
175P Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study Open
View article: 150MO Safety results from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis
150MO Safety results from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis Open
View article: From the Editor’s Desk…
From the Editor’s Desk… Open
View article: Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab.
Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab. Open
Background: Preclinical models have shown that metabolic dysfunction-associated steatotic liver disease (MASLD)-related hepatocellular carcinoma (HCC) may exhibit reduced responsiveness to immunotherapy, especially for intrahepatic lesions…
View article: Corrigendum to ‘From the Editor's Desk▪▪▪’ [J Hepatol (2025) 549-552]
Corrigendum to ‘From the Editor's Desk▪▪▪’ [J Hepatol (2025) 549-552] Open
View article: Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study Open
Standard of care first‐line systemic treatment for advanced biliary tract cancer includes chemo‐immunotherapy with gemcitabine, cisplatin, and durvalumab, followed by maintenance durvalumab monotherapy. The present work aims to investigate…
View article: From the Editor’s Desk...
From the Editor’s Desk... Open
View article: THE CONCEPT OF “CONVERSE THERAPEUTIC HIERARCHY” FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA
THE CONCEPT OF “CONVERSE THERAPEUTIC HIERARCHY” FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA Open
Background. The clinical complexity of patients with hepatocellular carcinoma (HCC), the availability of multiple therapeutic options, and clinical therapeutic intents could make it challenging to identify an unequivocal limit between conv…
View article: The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers Open
Hepatobiliary malignancies encompass a spectrum of invasive carcinomas arising in the liver [hepatocellular carcinoma (HCC), bile ducts [intrahepatic cholangiocarcinoma (ICC), and extrahepatic cholangiocarcinoma (EHC)] and the gallbladder.…
View article: Correction to “New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe” [The Lancet Regional Health – Europe, volume 50, March 2025, 101170]
Correction to “New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe” [The Lancet Regional Health – Europe, volume 50, March 2025, 101170] Open
[This corrects the article DOI: 10.1016/j.lanepe.2024.101170.].
View article: Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence Open
This study provides real-world evidence supporting the long-term efficacy of atezolizumab plus bevacizumab (A+B) for unresectable hepatocellular carcinoma, showing survival outcomes similar to those achieved in clinical trials. These findi…
View article: ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab Open
A Higher ALBI grade was associated with an increased risk of gastrointestinal bleeding after receiving A+B, and outperformed the CP score in predicting worse survival.
View article: Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study Open
Background/Objectives: Systemic treatment for unresectable hepatocellular carcinoma (HCC) has rapidly advanced, with immune checkpoint inhibitors now the preferred first-line option. However, with multiple agents available and no establish…
View article: 106P Impact of molecular alterations in advanced biliary tract cancer (BTC) patients (pts) treated with cisplatin, gemcitabine, durvalumab (CGD): A large global study
106P Impact of molecular alterations in advanced biliary tract cancer (BTC) patients (pts) treated with cisplatin, gemcitabine, durvalumab (CGD): A large global study Open